Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company.
Biocon Biologics is engaged in developing high quality, affordable biosimilars that can expand access to a cutting-edge class of therapies to patients globally.
Biocon Biologics was formed in 2016. The company is headquartered in Bangalore, Karnataka, India, with offices in Singapore and London.
Biocon Biologics is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions.
Biocon Biologics has a large portfolio of biosimilars under global clinical development with three of these commercialized in at least one of the developed markets of EU, U.S. and Japan. Biocon Biologics has a product pipeline of 28 molecules, including 11 with Mylan, several with Sandoz and is developing many independently.
Biocon Biologics is backed by Tata Capital, Goldman Sachs, ADQ, and True North. The company raised rs 555 crores in a new round on Jan 07, 2021. This brings Biocon Biologics' total funding to ₹24.4B to date. The deal valued Biocon Biologics at $4.17B post money.